Logo

Dicerna Presents New Interim Data of PHYOX 3 OLE Study Evaluating Nedosiran for Primary Hyperoxaluria at ASN Week 2020

Share this

Dicerna Presents New Interim Data of PHYOX 3 OLE Study Evaluating Nedosiran for Primary Hyperoxaluria at ASN Week 2020

Shots:

  • The PHYOX 3 OLE study involves assessing of nedosiran in participants aged ≥6yrs. with PH1 or PH2 who have participated in any previous PHYOX clinical development program trial as well as their siblings aged 6-18yrs. with PH
  • All participants regardless of PH subtype- achieved normal or near-normal Uox excretion @day180- 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion at one or more visits- 62% participants (70% & 33% with PH1 & PH2) demonstrated normalized Uox excretions on at least three consecutive visits- maximum reduction in Uox excretion (70.9%)
  • Nedosiran is an investigational candidate in development for the treatment of all three known types of PH – PH1- PH2- and PH3- act by inhibiting the LDH enzyme

 ­ Ref: Dicerna | Image: PRNewswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions